FAMICORD AG (V3V.DE) Stock Fundamental Analysis
FRA:V3V - Deutsche Boerse Ag - DE000A0BL849 - Common Stock - Currency: EUR
Overall V3V gets a fundamental rating of 4 out of 10. We evaluated V3V against 24 industry peers in the Health Care Providers & Services industry. V3V may be in some trouble as it scores bad on both profitability and health. V3V is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
V3V had positive earnings in the past year.
V3V had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: V3V reported negative net income in multiple years.
V3V had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
V3V has a Return On Assets (1.61%) which is comparable to the rest of the industry.
With a decent Return On Equity value of 10.63%, V3V is doing good in the industry, outperforming 60.87% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.61% | ||
| ROE | 10.63% | ||
| ROIC | N/A |
ROA(3y)-7.04%
ROA(5y)-3.48%
ROE(3y)-60.2%
ROE(5y)-34.49%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
V3V has a Profit Margin of 3.20%. This is in the better half of the industry: V3V outperforms 60.87% of its industry peers.
Looking at the Gross Margin, with a value of 36.66%, V3V is in line with its industry, outperforming 56.52% of the companies in the same industry.
V3V's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 3.2% | ||
| GM | 36.66% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.67%
GM growth 5Y-8.9%
2. Health
2.1 Basic Checks
V3V does not have a ROIC to compare to the WACC, probably because it is not profitable.
V3V has more shares outstanding than it did 1 year ago.
The number of shares outstanding for V3V has been increased compared to 5 years ago.
V3V has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 0.46, we must say that V3V is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of 0.46, V3V is not doing good in the industry: 82.61% of the companies in the same industry are doing better.
The Debt to FCF ratio of V3V is 2.09, which is a good value as it means it would take V3V, 2.09 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of V3V (2.09) is better than 95.65% of its industry peers.
A Debt/Equity ratio of 0.56 indicates that V3V is somewhat dependend on debt financing.
V3V has a Debt to Equity ratio of 0.56. This is amongst the best in the industry. V3V outperforms 82.61% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.56 | ||
| Debt/FCF | 2.09 | ||
| Altman-Z | 0.46 |
ROIC/WACCN/A
WACC6.01%
2.3 Liquidity
A Current Ratio of 0.76 indicates that V3V may have some problems paying its short term obligations.
With a Current ratio value of 0.76, V3V is not doing good in the industry: 60.87% of the companies in the same industry are doing better.
A Quick Ratio of 0.70 indicates that V3V may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.70, V3V is in line with its industry, outperforming 52.17% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.76 | ||
| Quick Ratio | 0.7 |
3. Growth
3.1 Past
V3V shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 109.51%, which is quite impressive.
The Revenue has been growing slightly by 7.73% in the past year.
Measured over the past years, V3V shows a very strong growth in Revenue. The Revenue has been growing by 30.44% on average per year.
EPS 1Y (TTM)109.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%160%
Revenue 1Y (TTM)7.73%
Revenue growth 3Y57.65%
Revenue growth 5Y30.44%
Sales Q2Q%8.91%
3.2 Future
V3V is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 32.64% yearly.
Based on estimates for the next years, V3V will show a quite strong growth in Revenue. The Revenue will grow by 14.02% on average per year.
EPS Next Y58.33%
EPS Next 2Y35.4%
EPS Next 3Y32.64%
EPS Next 5YN/A
Revenue Next Year9.33%
Revenue Next 2Y6.14%
Revenue Next 3Y5.07%
Revenue Next 5Y14.02%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 29.86 indicates a quite expensive valuation of V3V.
V3V's Price/Earnings ratio is a bit more expensive when compared to the industry. V3V is more expensive than 60.87% of the companies in the same industry.
When comparing the Price/Earnings ratio of V3V to the average of the S&P500 Index (29.43), we can say V3V is valued inline with the index average.
V3V is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 29.86 | ||
| Fwd PE | N/A |
4.2 Price Multiples
65.22% of the companies in the same industry are more expensive than V3V, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of V3V indicates a somewhat cheap valuation: V3V is cheaper than 65.22% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.22 | ||
| EV/EBITDA | 8.72 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
V3V's earnings are expected to grow with 32.64% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.51
PEG (5Y)N/A
EPS Next 2Y35.4%
EPS Next 3Y32.64%
5. Dividend
5.1 Amount
No dividends for V3V!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:V3V (2/25/2025, 7:00:00 PM)
4.18
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners2.65%
Inst Owner ChangeN/A
Ins Owners58.45%
Ins Owner ChangeN/A
Market Cap73.74M
Analysts84
Price Target6.43 (53.83%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0.16
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)37.5%
EPS NY rev (3m)37.5%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.23%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 29.86 | ||
| Fwd PE | N/A | ||
| P/S | 0.91 | ||
| P/FCF | 8.22 | ||
| P/OCF | 6.09 | ||
| P/B | 3.04 | ||
| P/tB | N/A | ||
| EV/EBITDA | 8.72 |
EPS(TTM)0.14
EY3.35%
EPS(NY)-0.02
Fwd EYN/A
FCF(TTM)0.51
FCFY12.17%
OCF(TTM)0.69
OCFY16.42%
SpS4.57
BVpS1.38
TBVpS-1.68
PEG (NY)0.51
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.61% | ||
| ROE | 10.63% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 3.2% | ||
| GM | 36.66% | ||
| FCFM | 11.13% |
ROA(3y)-7.04%
ROA(5y)-3.48%
ROE(3y)-60.2%
ROE(5y)-34.49%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.67%
GM growth 5Y-8.9%
F-Score7
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.56 | ||
| Debt/FCF | 2.09 | ||
| Debt/EBITDA | 1.65 | ||
| Cap/Depr | 35.61% | ||
| Cap/Sales | 3.89% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 147.25% | ||
| Profit Quality | 347.6% | ||
| Current Ratio | 0.76 | ||
| Quick Ratio | 0.7 | ||
| Altman-Z | 0.46 |
F-Score7
WACC6.01%
ROIC/WACCN/A
Cap/Depr(3y)60.39%
Cap/Depr(5y)47.49%
Cap/Sales(3y)7.53%
Cap/Sales(5y)6.03%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)109.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%160%
EPS Next Y58.33%
EPS Next 2Y35.4%
EPS Next 3Y32.64%
EPS Next 5YN/A
Revenue 1Y (TTM)7.73%
Revenue growth 3Y57.65%
Revenue growth 5Y30.44%
Sales Q2Q%8.91%
Revenue Next Year9.33%
Revenue Next 2Y6.14%
Revenue Next 3Y5.07%
Revenue Next 5Y14.02%
EBIT growth 1Y97.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year488.57%
EBIT Next 3Y98.08%
EBIT Next 5YN/A
FCF growth 1Y198.46%
FCF growth 3Y20.6%
FCF growth 5Y6%
OCF growth 1Y520.19%
OCF growth 3Y37.37%
OCF growth 5Y14.78%